A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin

NCT01592240 Phase 2 COMPLETED Results posted

To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	354
Start date	2012-07
Completion	2013-05

Conditions

• Hypercholesterolemia

Interventions

• PBO
• 200mg PF-04950615 (RN316)
• 300mg PF-04950615 (RN316)
• PBO
• PF-04950615
• PF-04950615
• PF-04950615

Primary outcomes

• Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — Baseline, Week 12

Countries

United States